# Retatrutide FAQ: 22 Common Questions, Answered from the Trial Record > Retatrutide questions answered from published clinical trial data — Phase 2 results, FDA status, mechanism, half-life, MASLD liver data, and comparisons with tirzepatide and semaglutide. ## Does retatrutide reduce liver fat in MASLD patients? Yes — in a dedicated Phase 2a substudy in 98 participants with obesity and MASLD (fatty liver disease), retatrutide 12 mg reduced liver fat by −82.4% at 24 weeks as measured by MRI-PDFF. Eighty-six percent of participants at that dose reached normal liver fat (below 5%) [5]. Reductions were sustained to −86.0% at 48 weeks. These are among the most dramatic liver-fat reductions reported for any investigational anti-obesity compound. ## What does retatrutide do? Retatrutide activates three metabolic hormone receptors at once: GLP-1 (suppresses appetite, slows gastric emptying), GIP (enhances post-meal insulin secretion, adipose remodeling), and glucagon (raises energy expenditure, drives liver fat breakdown). The triple action produces larger weight loss and metabolic improvement than single or dual agonists in trials to date. It is investigational — not an approved drug — developed by Eli Lilly and currently in Phase 3 trials [6]. ## How does retatrutide work? Retatrutide is a single synthetic peptide engineered to bind and activate GLP-1, GIP, and glucagon receptors simultaneously. GLP-1 signaling reduces appetite and food intake. GIP signaling amplifies insulin secretion after meals. Glucagon signaling raises the body's calorie-burning rate and drives hepatic lipid oxidation. Phase 2 trials showed the combination produces a mean −24.2% body-weight change at 12 mg over 48 weeks, versus −2.1% with placebo [1]. ## How to reconstitute retatrutide? No approved reconstitution protocol exists for retatrutide — it is an investigational compound with no FDA-approved formulation. The question applies to gray-market research vials, for which no verified stability data, endotoxin limits, or sterility specifications exist. Clinical trial investigators administer pre-formulated vials under clinical oversight; there is no authorized equivalent for non-trial use. The FDA issued more than 50 warning letters to gray-market retatrutide vendors in 2025. ## Is retatrutide FDA approved? No. Retatrutide is not approved by the FDA or any regulatory agency as of mid-2026. It is in Phase 3 clinical trials (the TRIUMPH program) conducted by Eli Lilly. FDA approval requires completion of Phase 3 trials, data analysis, and a New Drug Application review — a process not yet initiated. Retatrutide should not be confused with tirzepatide or semaglutide, which are separate compounds that are approved. ## When will retatrutide be available? No confirmed timeline exists. Phase 3 TRIUMPH trials are active as of mid-2026. Regulatory review would follow trial completion and NDA submission. Analyst modeling has speculated about a 2026–2027 filing window, but Eli Lilly has not confirmed a submission date. Until Phase 3 data are published and a regulatory filing is made, any specific availability date is speculation. This site will note when Phase 3 data are published. ## How to take retatrutide? In clinical trials, retatrutide was administered as a subcutaneous injection — injected into the fatty tissue just under the skin — once weekly. This is the only administration route studied in published trials. All trial doses were administered by clinical staff or study participants trained under clinical supervision. Retatrutide is not an approved drug, and "how to take" it as a medical instruction does not apply outside clinical trial enrollment. ## How long does retatrutide take to work? Phase 2 trial data show dose-dependent body-weight change beginning from the first weeks of treatment, with the steepest rate of loss typically in the first 20–24 weeks. At 12 mg, mean body-weight change at 48 weeks was −24.2% [1]. For liver fat, the MASLD substudy documented −82.4% reduction in liver fat by week 24 [5]. The Phase 1b data established a ~6-day half-life, meaning steady-state plasma levels are reached after approximately 4–5 weekly doses [4]. ## Is retatrutide better than tirzepatide? No head-to-head trial has been published. A systematic review of 26 RCTs in 15,491 adults without diabetes found retatrutide 12 mg produced the largest single weight-loss figure (22.1% at 48 weeks) among agents reviewed, versus tirzepatide 15 mg at 17.8% at 72 weeks — but the comparison is descriptive, not a formal ranking, as heterogeneity in trial populations and durations prevented pooled meta-analysis [9]. A TRIUMPH active-comparator trial vs tirzepatide is ongoing. ## How much retatrutide per week? In Phase 2 clinical trials, doses of 1 mg, 4 mg, 8 mg, and 12 mg once weekly were studied in the obesity and MASLD trials [1, 5]. In the type 2 diabetes trial, doses escalated from 0.5 mg to 12 mg weekly over the study period [2]. These are study-design facts from published protocols — not a dosing instruction, prescription, or recommendation for use outside a clinical trial. ## How to mix retatrutide with bacteriostatic water? No approved mixing protocol exists for retatrutide. Clinical trial formulations are pre-prepared investigational drug products administered under clinical supervision — not reconstituted from lyophilized powder in research settings. For gray-market peptide vials, the question is conventionally applied to a general peptide-reconstitution practice, but no stability data or official guidance covers retatrutide specifically in this context. Gray-market retatrutide vendors have received FDA warning letters; such products are unregulated. ## How to switch from tirzepatide to retatrutide? No clinical guidance exists for switching between tirzepatide and retatrutide. Retatrutide is not an approved drug; tirzepatide is approved for specific indications. Any transition between these compounds in a clinical context would be managed by a treating physician under current labeling and evolving clinical literature. A network meta-analysis found both agents significantly improve metabolic outcomes including liver fat markers, but no trial has studied transitions between them [12]. ## Is retatrutide a GLP-3? No. "GLP-3" is a misnomer that circulates in lay discussions of retatrutide. There is no GLP-3 receptor — the term does not correspond to a biological target. Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors. The "GLP-3" label appears to arise from confusion about the compound's third receptor target (glucagon) or a misreading of the "triple" designation. The correct characterization is GIP/GLP-1/glucagon receptor triagonist [3]. ## Is retatrutide available? Retatrutide is not commercially available as an approved drug. Access is limited to enrolled participants in clinical trials. A gray market of research-labeled vials exists outside clinical trials, but those products are unregulated, of unverified identity and purity, and not the same compound as the clinical-trial investigational drug. The FDA issued more than 50 warning letters to retatrutide vendors in 2025 citing FD&C Act violations. ## What is retatrutide used for? In clinical trials, retatrutide is being studied for obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD / fatty liver), cardiovascular risk reduction, and chronic kidney disease. No approved indication exists — the compound is investigational. Phase 2 trials have demonstrated mean weight loss of −24.2% at 48 weeks in obesity, HbA1c reduction of −2.02 percentage points in type 2 diabetes, and liver-fat reduction of −82.4% in MASLD [1, 2, 5]. ## What receptors does retatrutide target? Retatrutide targets three receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). Cryo-EM structural analysis confirmed engagement of all three at measured relative potencies of approximately 8.9× native GIP at GIPR, 0.3× at GCGR, and 0.4× at GLP-1R versus their respective endogenous hormones [3]. The triple-agonist design is what distinguishes retatrutide from approved GLP-1–only and GLP-1/GIP dual agonists. ## Is retatrutide legal? Retatrutide as an approved pharmaceutical does not exist, so the question of prescription legality is moot — there is no approved product to be prescribed. Research-labeled retatrutide sold outside clinical trials is unregulated material. In the US, marketing or selling such products can violate the FD&C Act, as demonstrated by the FDA's 2025 wave of warning letters to vendors. Possession for personal research use occupies an undefined legal space that varies by jurisdiction. Athletes should consult the current WADA Prohibited List; GLP-1/GIP/glucagon agonists are not specifically named-prohibited as of the current code, but status of investigational agents can change. ## How often do you take retatrutide? All published clinical trials used once-weekly subcutaneous dosing [1, 2, 4, 5]. The ~6-day half-life of retatrutide supports this interval by maintaining meaningful plasma concentrations between doses [4]. No alternative dosing frequency has been studied or published. Once-weekly injection is the schedule used across all Phase 1, Phase 2, and Phase 3 trials. ## What is the half-life of retatrutide? Approximately 6 days, established in the Phase 1b first-in-human trial [4]. This extended half-life is engineered via C20 fatty-diacid acylation of the peptide, which enables reversible albumin binding. Albumin acts as a circulating depot, releasing the active peptide slowly over days. The ~6-day half-life supports once-weekly dosing, steady-state accumulation after 4–5 doses, and several weeks of clearance after discontinuation. ## How to store retatrutide? No approved storage specification exists for retatrutide — it has no approved pharmaceutical formulation. Clinical trial investigational product is handled under GMP (good manufacturing practice) cold-chain requirements; those specifications are not in the public domain. For general peptide handling context: lyophilized peptides are typically stored at −20°C or colder, with reconstituted solutions stored refrigerated (2–8°C) for limited periods. These are general pharmaceutical conventions, not authoritative storage instructions for retatrutide. ## Is retatrutide the same as Ozempic? No. Retatrutide and semaglutide (the compound sold under brand names this site does not use, per editorial policy) are distinct molecules with different mechanisms. Semaglutide is a GLP-1 receptor agonist only — it activates one receptor. Retatrutide is a triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously. Semaglutide is approved; retatrutide is investigational. They are in the same therapeutic class but are different compounds. ## Is retatrutide better than semaglutide? No head-to-head published trial exists. Descriptive comparison from the Moiz et al. systematic review (26 RCTs, 15,491 adults without diabetes) placed retatrutide 12 mg at a 22.1% weight-loss figure at 48 weeks versus 13.9% for semaglutide 2.4 mg at 68 weeks — a longer trial in the semaglutide arm [9]. The comparison is not a formal ranking, and no meta-analysis was performed due to trial heterogeneity. A meaningful comparison awaits the TRIUMPH active-comparator arm or a purpose-built head-to-head study. --- An independent appraisal of the published retatrutide trial record — each figure traced to its study, the Phase 3 questions held open, nothing here prescribed or dispensed.